Document is current
Any future updates will be listed below
-
Authors
Nakano, Kiyotaka https://orcid.org/0000-0002-0285-2464
Oki, Eiji https://orcid.org/0000-0002-9763-9366
Yamazaki, Masaki https://orcid.org/0000-0002-2079-0084
Suzuki, Masami https://orcid.org/0009-0009-9629-7622
Kawai, Shigeto
Fujita, Takanori
Kato, Atsuhiko
Zaitsu, Yoko
Jogo, Tomoko
Kato, Chie
Watanabe, Takeshi
Hashimoto, Eri
Nishime, Chiyoko
Fujii, Etsuko
Ando, Koji
Nagae, Genta
Harimoto, Norifumi
Ota, Mitsuhiko
Saeki, Hiroshi
Aburatani, Hiroyuki
Maehara, Yoshihiko
Yamazaki, Tatsumi
- License Information
-
More Information
Article History
Received: 1 November 2024
Revised: 16 May 2025
Accepted: 11 June 2025
First Online: 20 June 2025
Competing interests
: KN, MY, SK, AK, CK, EH, and EF are employees of Chugai Pharmaceutical Co., Ltd. TW is an employee of Chugai Research Institute for Medical Science, Inc. MS and CN are employees of Central Institute for Experimental Medicine and Life Science. TY is a board member of Central Institute for Experimental Medicine and Life Science. MY, MS, SK, KN, and TY have submitted a provisional patent filing on the organoid system. Chugai Pharmaceutical Co., Ltd., and Kyushu University have a collaborative research agreement. Chugai Pharmaceutical Co., Ltd., Ltd., and the University of Tokyo have a collaborative research agreement. Chugai Pharmaceutical Co., Ltd. provided PLR123 cells to the Central Institute for Experimental Animals under a Material Transfer Agreement.
